文献速递脑血管病神经重症与神经感染

溶栓急性缺血性卒中早期收缩压控制与结局的ENCHANTED研究

Associations of Early Systolic Blood Pressure Control and Outcome After Thrombolysis-Eligible Acute Ischemic Stroke: Results From the ENCHANTED Study.
PubMed 文献 · Stroke · 2021-10-27

ENCHANTED试验事后分析纳入4511例接受溶栓且收缩压150-180 mmHg的急性缺血性卒中患者,评估随机后24小时内收缩压均值、变异性和1小时降幅与90天功能结局及颅内出血的关系。结果显示较低的收缩压均值和较小的收缩压变异性与更好的功能结局相关,且与颅内出血风险降低相关,而1小时收缩压降幅与结局无关。

要点

  • 溶栓后24小时内收缩压均值每升高10 mmHg,功能结局良好的 odds 降低(OR 0.76)。
  • 收缩压变异性每增加1 SD,功能结局良好的 odds 降低(OR 0.86)。
  • 较高的收缩压均值和较大的变异性均与颅内出血风险增加相关。

核心结论

  • 溶栓急性缺血性卒中患者早期达到并维持收缩压<140 mmHg(甚至110-120 mmHg)与更好的功能结局相关。

研究设计与样本

  • ENCHANTED试验(部分析因设计)的事后分析,纳入4511例接受溶栓且收缩压150-180 mmHg的急性缺血性卒中患者。

主要发现

  • 收缩压均值每升高10 mmHg,改良Rankin量表 favorable shift 的OR为0.76(95%CI 0.71-0.82;P<0.001)。
  • 收缩压变异性(1-24小时SD)每增加1单位,favorable shift 的OR为0.86(95%CI 0.76-0.98;P=0.025)。
  • 收缩压均值每升高10 mmHg,颅内出血的OR为1.18(95%CI 1.06-1.31;P=0.002)。
  • 收缩压变异性每增加1单位,颅内出血的OR为1.34(95%CI 1.11-1.62;P=0.002)。
  • 1小时收缩压降幅与功能结局(OR 0.98,95%CI 0.93-1.04;P=0.564)和颅内出血(OR 1.05,95%CI 0.98-1.14;P=0.184)均无关。

关键数值与推荐

  • 强化降压目标为收缩压130-140 mmHg,指南推荐目标为收缩压<180 mmHg。
  • 溶栓剂量为低剂量阿替普酶0.6 mg/kg或标准剂量0.9 mg/kg。

临床怎么用

  • 溶栓后应尽早达到并稳定维持收缩压<140 mmHg,避免血压波动。
  • 关注24小时内收缩压的均值水平和变异性,而非单纯追求快速大幅降压。

局限性

  • 本研究为事后分析,结果需前瞻性研究验证。
  • 研究人群收缩压基线为150-180 mmHg,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: In thrombolysis-eligible patients with acute ischemic stroke, there is uncertainty over the most appropriate systolic blood pressure (SBP) lowering profile that provides an optimal balance of potential benefit (functional recovery) and harm (intracranial hemorrhage). We aimed to determine relationships of SBP parameters and outcomes in thrombolyzed acute ischemic stroke patients. METHODS: Post hoc analyzes of the ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study), a partial-factorial trial of thrombolysis-eligible and treated acute ischemic stroke patients with high SBP (150-180 mm Hg) assigned to low-dose (0.6 mg/kg) or standard-dose (0.9 mg/kg) alteplase and intensive (target SBP, 130-140 mm Hg) or guideline-recommended (target SBP <180 mm Hg) treatment. All patients were followed up for functional status and serious adverse events to 90 days. Logistic regression models were used to analyze 3 SBP summary measures postrandomization: attained (mean), variability (SD) in 1-24 hours, and magnitude of reduction in 1 hour. The primary outcome was a favorable shift on the modified Rankin Scale. The key safety outcome was any intracranial hemorrhage. RESULTS: Among 4511 included participants (mean age 67 years, 38% female, 65% Asian) lower attained SBP and smaller SBP variability were associated with favorable shift on the modified Rankin Scale (per 10 mm Hg increase: odds ratio, 0.76 [95% CI, 0.71-0.82]; P<0.001 and 0.86 [95% CI, 0.76-0.98]; P=0.025) respectively, but not for magnitude of SBP reduction (0.98, [0.93-1.04]; P=0.564). Odds of intracranial hemorrhage was associated with higher attained SBP and greater SBP variability (1.18 [1.06-1.31]; P=0.002 and 1.34 [1.11-1.62]; P=0.002) but not with magnitude of SBP reduction (1.05 [0.98-1.14]; P=0.184). CONCLUSIONS: Attaining early and consistent low levels in SBP <140 mm Hg, even as low as 110 to 120 mm Hg, over 24 hours is associated with better outcomes in thrombolyzed acute ischemic stroke patients. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01422616.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Wang X, Minhas JS, Moullaali TJ, et al. Associations of Early Systolic Blood Pressure Control and Outcome After Thrombolysis-Eligible Acute Ischemic Stroke: Results From the ENCHANTED Study. Stroke. 2021. PMID: 34702064. doi:10.1161/STROKEAHA.121.034580

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。